Evangelia Petsalaki: New Systems Biology Approach Identifies Biomarkers in Thrombotic APS
Evangelia Petsalaki, Director of Oncology Data Science Innovation at GSK and Visiting Group Leader at EMBL-EBI, shared on LinkedIn about a recent article she and her colleagues co-authored, published in medRxiv, adding:
”We’re pleased to share our latest preprint on thrombotic primary antiphospholipid syndrome (APS).
In this study, we integrated plasma proteomics, whole-blood transcriptomics, machine learning and network-based analysis to investigate the molecular programmes associated with high-risk disease.
Across multiple complementary analyses, we found evidence for a complement- and interferon-associated thromboinflammatory programme linked to increasing antiphospholipid antibody burden and recurrent thrombosis. Integrating the data using multi-omics factor analysis and network propagation also connected circulating protein signatures to intracellular signalling pathways, providing a systems-level view of disease biology.
Among the findings, Complement Factor D (CFD) emerged as a candidate biomarker associated with recurrent thrombosis, although this will require validation in independent cohorts.
This work was a fantastic collaboration between colleagues at EMBL-EBI, the National and Kapodistrian University of Athens, and the Biomedical Sciences Research Center ‘Alexander Fleming’.
Many thanks to everyone involved, especially Srijith Sasikumar and Maria Tektonidou as well as our coauthors Michail Baltsiotis, Kleio-Maria Verrou, Georgia Rouni, Martina Samiotaki, Petros Sfikakis and the rest of the team.”
Title: Multi-omics and network propagation reveal latent innate immune programmes stratifying high-risk thrombotic primary antiphospholipid syndrome
Authors: Srijith Sasikumar, Michail Baltsiotis, Kleio-Maria Verrou, Georgia Rouni, Petros P. Sfikakis, Martina Samiotaki, Evangelia Petsalaki, Maria G. Tektonidou
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 12, 2026, 21:51Sam Botchey: Orthobiologics Are Advancing but the Evidence Must Keep Pace
-
Oct 12, 2026, 21:50Serum Vitamin D, Platelet Function, and Bleeding in Primary ITP – Platelets Journal
-
Oct 12, 2026, 21:30Nika Samadzadeh Tabrizi: Looking Forward to the PACeS Trial on Anticoagulation for POAF
-
Oct 12, 2026, 21:28Michael Megaly: Does Coronary Ectasia Affect Outcomes in Acute Coronary Syndromes?
-
Oct 12, 2026, 21:25Vitor Borin P. de Souza: Think Twice Before Anticoagulating an Isolated Subsegmental PE
-
Oct 12, 2026, 20:43Jazlyn A Selvasingh: Excited to Share Our Research at AAO-HNSF 2026 in Los Angeles
-
Oct 12, 2026, 20:31Natalia Kovtun: Higher Ferritin Cutoffs Now Define Iron Deficiency
-
Oct 12, 2026, 19:39Edward Loftus: Using Low-Dose Aspirin in Pregnant Women With IBD
-
Oct 12, 2026, 19:32Shruti Sachdeva: Strengthening the Fight against Anemia